1887
Volume 2012, Issue 1
  • ISSN: 2305-7823
  • E-ISSN:

Abstract

Abstract

The term “cardiomyopathies” was used for the first time 55 years ago, in 1957. Since then awareness and knowledge of this important and complex group of heart muscle diseases have improved substantially. Over these past five decades a large number of definitions, nomenclature and schemes, have been advanced by experts and consensus panel, which reflect the fast and continued advance of the scientific understanding in the field.

Cardiomyopathies are a heterogeneous group of inherited myocardial diseases, which represent an important cause of disability and adverse outcome. Although considered rare diseases, the overall estimated prevalence of all cardiomyopathies is at least 3% in the general population worldwide. Furthermore, their recognition is increasing due to advances in imaging techniques and greater awareness in both the public and medical community.

Cardiomyopathies represent an ideal translational model of integration between basic and clinical sciences. A multidisciplinary approach is therefore essential in order to ensure their correct diagnosis and management.

In the present work, we aim to provide a concise overview of the historical background, genetic and phenotypic spectrum and evolving concepts leading to the various attempts of cardiomyopathy classifications produced over the decades.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2012.4
2012-07-03
2019-08-20
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2012/1/gcsp.2012.4.html?itemId=/content/journals/10.5339/gcsp.2012.4&mimeType=html&fmt=ahah

References

  1. [1]. Brigden   W. Uncommon myocardial diseases: the non-coronary cardiomyopathies. . Lancet . 1957Dec. 21; ;273: : 7008 , 1243– 1249 .
    [Google Scholar]
  2. [2]. Goodwin   JF., , Gordon   H., , Hollman   A., and Bishop   MB. Clinical aspects of cardiomyopathy. . Br Med J . 1961 Jan. 14; ;1: : 5219 , 69– 79 .
    [Google Scholar]
  3. [3]. Report of the WHO/ISFC Task Force on the definition and classification ofcardiomyopathies. Br Heart J. 1980;44, 672–673.
  4. [4]. Watkins   H., , Ashrafian   H., and Redwood   C. Inherited cardiomyopathies. . N Engl J Med . 2011 Apr. 28; ;364: : 17 , 1643– 1656 .
    [Google Scholar]
  5. [5]. Bos   JM., , Towbin   JA., and Ackerman   MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing forhypertrophic cardiomyopathy. . J Am Coll Cardiol . 2009 July 14; ;54: : 3 , 201– 211 .
    [Google Scholar]
  6. [6]. Richardson   P., , McKenna   W., , Bristow   M., , Maisch   B., , Mautner   B., , O’Connell   J., , Olsen   E., , Thiene   G., and Goodwin   J. Report of the 1995 World Health Organization/International Society and Federationof Cardiology Task Force on the definition and classification of cardiomyopathies. . Circulation . 1996; ;93: : 841– 842 .
    [Google Scholar]
  7. [7]. Maron   BJ., , Towbin   JA., , Thiene   G., , Antzelevitch   C., , Corrado   D., , Arnett   D., , Moss   AJ., , Seidman   C., and Young   JB. Contemporary definitions and classification of the cardiomyopathies. An AmericanHeart Association scientific statement from the Council on Clinical Cardiology, HeartFailure and Transplantation Committee; Quality of Care and Outcomes Research andFunctional Genomics and Translational Biology Interdisciplinary Working Groups;and Council on Epidemiology and Prevention. . Circulation . 2006; ;113: : 1807– 1816 .
    [Google Scholar]
  8. [8]. Elliott   P., , Anderson   B., , Arbustini   E., , Bilinska   Z., , Cecchi   F., , Charron   P., , Dubourg   O., , Kuhl   U., , Maisch   B., , McKenna   WJ., , Monserrat   L., , Pankuweit   S., , Rapezzi   C., , Seferovic   P., , Tavazzi   L., and Keren   A. Classification of cardiomyopathies: a position statement from the European workinggroup on myocardial and pericardial diseases. . Eur Heart J . 2008; ;29: : 270– 276 .
    [Google Scholar]
  9. [9]. Rapezzi   C., , Quarta   CC., , Riva   L., , Longhi   S., , Gallelli   I., , Lorenzini   M., , Ciliberti   P., , Biagini   E., , Salvi   F., and Branzi   A. Transthyretin-related amyloidoses and the heart: a clinical overview. . Nat RevCardiol . 2010 July; ;7: : 7 , 398– 408 .
    [Google Scholar]
  10. [10]. Jacoby   D., and McKenna   WJ. Genetics of inherited cardiomyopathy. . Eur Heart J . 2012 Feb.; ;33: : 3 , 296– 304 .
    [Google Scholar]
  11. [11]. Olivotto   I, , Girolami   F, and Ackerman   MJ   et al.   Myofilament protein gene mutation screening and outcome of patients withhypertrophic cardiomyopathy. . Mayo Clin Proc . 2008 June; ;83: : 6 , 630– 638 .
    [Google Scholar]
  12. [12]. Friedrich   FW., and Carrier   L. Genetics of hypertrophic and dilated cardiomyopathy. . Curr Pharm Biotechnol . 2012Jan. 20; ; [Epub ahead of print] .
    [Google Scholar]
  13. [13]. Herman   DS., , Lam   L., , Taylor   MR., , Wang   L., , Teekakirikul   P., , Christodoulou   D., , Conner   L., , DePalma   SR., , McDonough   B., , Sparks   E., , Teodorescu   DL., , Cirino   AL., , Banner   NR., , Pennell   DJ., , Graw   S., , Merlo   M., , Di Lenarda   A., , Sinagra   G., , Bos   JM., , Ackerman   MJ., , Mitchell   RN., , Murry   CE., , Lakdawala   NK., , Ho   CY., , Barton   PJ., , Cook   SA., , Mestroni   L., , Seidman   JG., and Seidman   CE. Truncations of titin causing dilated cardiomyopathy. . N Engl J Med . 2012 Feb.16; ;366: : 7 , 619– 628 .
    [Google Scholar]
  14. [14]. Olivotto I, Kassem HS and Girolami F. Genetic testing forhypertrophic cardiomyopathy: ongoing voyage from exploration to clinicalexploitation. DOI: 10.4081. Cardiogenetics. 2011.e3 Published: 2011-07-05 10:15:10.
  15. [15]. Charron   P., , Arad   M., , Arbustini   E., , Basso   C., , Bilinska   Z., , Elliott   P., , Helio   T., , Keren   A., , McKenna   WJ., , Monserrat   L., , Pankuweit   S., , Perrot   A., , Rapezzi   C., , Ristic   A., , Seggewiss   H., , van Langen   I., and Tavazzi   L. Genetic counselling and testing in cardiomyopathies: a position statement of theEuropean Society of Cardiology Working Group on Myocardial and PericardialDiseases. . Eur Heart J . 2010; ;31: : 2715– 2726 .
    [Google Scholar]
  16. [16]. Wang   L., , Seidman   JG., and Seidman   CE. Narrative review: harnessing molecular genetics for the diagnosis and management ofhypertrophic cardiomyopathy. . Ann Intern Med . 2010; ;152: : 513– 520 .
    [Google Scholar]
  17. [17]. Hershberger   RE, , Lindenfeld   J, and Mestroni   L   et al.   Genetic evaluation of cardiomyopathy- a Heart Failure Society of America practiceguideline. . J Card Fail . 2009; ;15: : 83– 97 .
    [Google Scholar]
  18. [18]. van Langen   IM, , Birnie   E, and Leschot   NJ   et al.   Genetic knowledge and counselling skills of Dutch cardiologists: sufficient forthegenomics era?. . Eur Heart J . 2003; ;24: : 560– 566 .
    [Google Scholar]
  19. [19]. Gersh   BJ., , Maron   BJ., , Bonow   RO., , Dearani   A., , Fifer   MA., , Link   MS., , Naidu   SS., , Nishimura   RA., , Ommen   SR., , Rakowski   H., , Seidman   CE., , Towbin   JA., , Udelson   JE., and Yancy   CW. ACCF/AHA guideline for the diagnosis and treatment of hypertrophiccardiomyopathy: executive summary: a report of the American College of CardiologyFoundation/American Heart Association Task Force on Practice Guidelines. . Circulation . 2011; ;124: : 2761– 2796 .
    [Google Scholar]
  20. [20]. Maron   MS, , Olivotto   I, and Zenovich   AG   et al.   Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflowtract obstruction. . Circulation . 2006; ;114: : 21 , 2232– 2239 .
    [Google Scholar]
  21. [21]. Maron   BJ. Contemporary insights and strategies for risk stratification and prevention ofsudden death in hypertrophic cardiomyopathy. . Circulation . 2010; ;121: : 445– 456 .
    [Google Scholar]
  22. [22]. Girolami   F., , Ho   CY., , Semsarian   C., , Baldi   M., , Will   ML., , Baldini   K., , Torricelli   F., , Yeates   L., , Cecchi   F., , Ackerman   MJ., and Olivotto   I. Clinical features and outcome of hypertrophic cardiomyopathy associated with triplesarcomere protein gene mutations. . J Am Coll Cardiol . 2010 Apr 6; ;55: : 14 , 1444– 1453 .
    [Google Scholar]
  23. [23]. Schapira   AH. Mitochondrial diseases. . Lancet . 2012 Apr 4; ; Epub ahead of print .
    [Google Scholar]
  24. [24]. Keren   A., , Syrris   P., and McKenna   W. Hypertrophic cardiomyopathy: the genetic determinants of clinical diseaseexpression. . Nat Clin Pract Cardiovasc Med . Mar. 2008; ;5: : 3 , 158– 168 .
    [Google Scholar]
  25. [25]. Merlo   M., , Pyxaras   SA., , Pinamonti   B., , Barbati   G., , Di Lenarda   A., and Sinagra   G. Prevalence and prognostic significance of left ventricular reverse remodeling indilated cardiomyopathy receiving tailored medical treatment. . J Am Coll Cardiol . 2011; ;57: : 13 , 1468– 1476 .
    [Google Scholar]
  26. [26]. Parks   SB., , Kushner   JD., , Nauman   D., , Burgess   D., , Ludwigsen   S., , Peterson   A., , Li   D., , Jakobs   P., , Litt   M., , Porter   CB., , Rahko   PS., and Hershberger   RE. Lamin A/C mutation analysis in a cohort of 324 unrelated patients withidiopathic or familial dilated cardiomyopathy. . Am Heart J . 2008; ;156: : 161– 169 .
    [Google Scholar]
  27. [27]. van Berlo   JH, , de Voogt   WG, and van der Kooi   AJ   et al.   Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: dolamin A/C mutations portend a high risk of sudden death?. . J Mol Med . 2005; ;83: : 79– 83 .
    [Google Scholar]
  28. [28]. Meune   C., , Van Berlo   JH., , Anselme   F., , Bonne   G., , Pinto   YM., and Duboc   D. Primary prevention of sudden death in patients with lamin A/C gene mutations. . NEngl J Med . 2006; ;354: : 209– 210 .
    [Google Scholar]
  29. [29]. Mocumbi   AO., , Yacoub   S., and Yacoub   MH. Neglected tropical cardiomyopathies: II. Endomyocardial fibrosis: myocardial disease. . Heart . 2008 Mar.; ;94: : 3 , 384– 390 .
    [Google Scholar]
  30. [30]. Kubo   T, , Gimeno   JR, and Bahl   A   et al.   Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathywith restrictive phenotype. . Journal of the American College of Cardiology . June2007; ;49: : 25 , 2419– 2426 .
    [Google Scholar]
  31. [31]. Zangwill   SD., , Naftel   D., , L’Ecuyer   T., , Rosenthal   D., , Robinson   B., , Kirklin   JK., , Stendahl   G., and Dipchand   AI. Pediatric Heart Transplant Study Investigators. Outcomes of children withrestrictive cardiomyopathy listed for heart transplant: a multi-institutional study. . JHeart Lung Transplant . 2009 Dec; ;28: : 12 , 1335– 1340 .
    [Google Scholar]
  32. [32]. Marcus   FI., , McKenna   WJ., , Sherrill   D., , Basso   C., , Bauce   B., , Bluemke   DA., , Calkins   H., , Corrado   D., , Cox   MG., , Daubert   JP., , Fontaine   G., , Gear   K., , Hauer   R., , Nava   A., , Picard   MH., , Protonotarios   N., , Saffitz   JE., , Sanborn   DM., , Steinberg   JS., , Tandri   H., , Thiene   G., , Towbin   JA., , Tsatsopoulou   A., , Wichter   T., and Zareba   W. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia:proposed modification of the Task Force Criteria. . Eur Heart J . 2010; ;31: : 806– 814 .
    [Google Scholar]
  33. [33]. Basso   C., , Bauce   B., , Corrado   D., and Thiene   G. Pathophysiology of arrhythmogenic cardiomyopathy. . Nat Rev Cardiol . 2011 Nov29; ;9: : 4 , 223– 233 .
    [Google Scholar]
  34. [34]. Ackerman   MJ, , Priori   SG, and Willems   S   et al.   HRS/EHRA Expert Consensus Statement on the State of Genetic Testing forChannelopathies and Cardiomyopathies. . Europace . 2011 Aug; ;13: : 8 , 1077– 109 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2012.4
Loading
/content/journals/10.5339/gcsp.2012.4
Loading

Data & Media loading...

Supplementary File 1

  • Article Type: Review Article
Keyword(s): cardiomyopathies , classification and myocardial disease
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error